Presentation charts for Q3 2013 Investor Conference Call on October 31, 2013

1. Investor Conference Call
Q3 2013 Results
October 31, 2013 / Marijn Dekkers, CEO

2. Disclaimer
This presentation may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in Bayer’s public reports which are
available on the Bayer website at www.bayer.com.
The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
Page 2 • Q3 2013 Investor Conference Call • Marijn Dekkers

3. Q3 2013 – Bayer Continues Encouraging
Business Development

Ongoing strong performance of Life Sciences, MaterialScience level
with prior-year quarter

New pharma product sales exceeding expectations, full-year target
raised to >€1.4bn

Earnings significantly impacted by negative currency effects

Full-year 2013 Group outlook maintained although increasingly
ambitious
Page 3 • Q3 2013 Investor Conference Call • Marijn Dekkers

4. Q3 2013 –
Encouraging Business Development
Sales
EBIT
in € million
% currency & portfolio adj.
9,661
EBITDA
Core EPS
in € million
adjusted**
in € million
in €
9,643
1,842
1,984
1.27
1,221
1.17
828
Q3’12*
Q3’13
+6%
Q3’12*
Q3’13
+47%
Page 4 • Q3 2013 Investor Conference Call • Marijn Dekkers
Q3’12*
Q3’13
+8%
Q3’12*
Q3’13
+9%
*Prior-year figures restated
**before special items

5. Q3 2013 – Regional Performance:
Growth Led By Emerging Economies
In € million, ∆% yoy Fx adjusted
Q3 2013 Group Sales by Region
Emerging
Economies¹
+9%
USA
+3%
20%
Emerging Economies
+1%
+18%
~1,500
40%
~1,400
+11%
31%
~500
9%
Western Europe
+5%
+6%
~400
Others²
+8%
Group €9,643m; +6%
Page 5 • Q3 2013 Investor Conference Call • Marijn Dekkers
Emerging
Asia³
Latin
America
Eastern
Europe
Africa &
Middle East
¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,
New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia w/o Japan, Australia, New Zealand

6. Q3 2013 –
Cash Flow And Net Debt Development
Cash Flow in € million, Net Debt in € billion
Q3 2013 Cash Flow
GCF
NCF
Net Debt Development
Investments
oFCF
-€1.3bn
7.7
1,367
∆
y-o-y
9.0
1,728
514
1,214
+36%
-13%
+6%
-19%
June 30, 2013
Page 6 • Q3 2013 Investor Conference Call • Marijn Dekkers
Sep 30, 2013

7. Q3 2013 – HealthCare: Organic Growth
Driven by New Products and Consumer Care
In € million, ∆% yoy, () = Fx & portf. adjusted
Sales
Consumer
Health
-3% (+3%)
Earnings1
36%
1,924
Pharma
+3% (+11%)
1,392
2,818
Adj.
EBIT*
Adj.
EBITDA*
+5%
1,331
915
+8%
1,006
1,048 +4%
847
633
HealthCare €4,742m; +1% (+7%)
Price
0%
Volume
+8%
Fx
-8%
Page 7 • Q3 2013 Investor Conference Call • Marijn Dekkers
Portfolio
+1%
484
477
+7%
371
-1%
-1%
373
Q3‘12 Q3‘13
677
Q3‘12 Q3‘13
1
*before special items
Prior-year figures restated.

8. Q3 2013 – CropScience:
Good Start to the Season in Latin America
In € million, ∆% yoy, () = Fx & portf. adjusted
Sales
Environmental Science
+8% (+19%)
68 140
Earnings1
Crop Protection
+6% (+14%)
Adj.
EBIT*
Adj.
EBITDA*
1,504
224
+14%
197
Seeds
-30% (-30%)
115 +51%
76
CropScience €1,712m; +4% (+12%)
Price
+3%
Volume
+9%
Fx
-8%
Page 8 • Q3 2013 Investor Conference Call • Marijn Dekkers
Portfolio
+1%
Q3‘12 Q3‘13
Q3‘12 Q3‘13
1
*before special items
Prior-year figures restated.

9. Q3 2013 - MaterialScience:
On Prior-Year Level
In € million, ∆% yoy, () = Fx & portf. adjusted
Sales
Polycarbonates
-6% (-3%)
Earnings1
Polyurethanes
0% (+4%)
673
1,567
337
CAS**
-5% (+1%)
Adj.
EBIT*
Adj.
EBITDA*
346
+3%
486
174
IO***
-9% (-7%)
186
+7%
171
MaterialScience €2,897m; -3% (+1%)
Price
-1%
Volume
+2%
Fx
-4%
Page 9 • Q3 2013 Investor Conference Call • Marijn Dekkers
Portfolio
0%
*before special items
Q3‘12 Q3‘13
**CAS: Coatings, Adhesives, Specialties
Q3‘12
Q3‘13
*** IO: Industrial Operations
1 Prior-year figures restated.

10. FY 2013 Group Outlook Maintained
Although Increasingly Ambitious
Sales ∆ Fx and portfolio adjusted, EBITDA before special items
20121
2013E
Sales
€39.7bn
+4-5% to
~€40bn*
adj. EBITDA
€8.3bn
mid-single-digit %
increase
Core EPS
€5.30
high-single-digit %
increase
Page 10 • Q3 2013 Investor Conference Call • Marijn Dekkers
*Assuming average Fx rates of 9M 2013
Outlook depends on specific planning assumptions as detailed in the Annual Report
1 2012 figures restated

11. Investor Conference Call
Q3 2013 Results
October 31, 2013 / Marijn Dekkers, CEO